Literature DB >> 17016056

Mechanism of inflammation in murine eosinophilic myocarditis produced by adoptive transfer with ovalbumin challenge.

Masao Hirasawa1, Yuko Ito, Masa-Aki Shibata, Yoshinori Otsuki.   

Abstract

BACKGROUND: Interleukin (IL)-5, RANTES and CC chemokine receptor 3 (CCR3) are essential for induction of eosinophil recruitment in organs, but the precise pathogenesis of eosinophilic myocarditis is still unclear. We investigated the relationships between these cytokines and receptors in the development of inflammation in murine myocarditis produced by adoptive transfer, with reference to eosinophil infiltration and signal transduction.
METHODS: The splenocytes from male donor DBA/2 mice were separated after ovalbumin (OVA) sensitization. These cells had a CD4/CD8 ratio of approximately 3.0. Cells (2.0 x 10(7)) were individually transfused to recipient adoptive male DBA/2 mice, and OVA challenge was performed serially. The heart and spleen of the recipient were analyzed to determine the kinetics of IL-5, RANTES, CCR3 and eosinophil production with simultaneous determination of Janus kinase 3 (JAK3) mRNA.
RESULTS: Approximately 85% of recipient mice developed myocarditis; 35% had recognizable cell infiltration in the left ventricular endocardium, an effect which was absent in control mice. Eosinophilic myocarditis was usually associated with animals having several degenerative changes in myocardial cells, and IL-5, RANTES and CCR3 expressions were usually present in these eosinophils (p < 0.05). CCR3 and JAK3 mRNAs were detected in the spleens and hearts of recipient animals providing histological evidence for kinetics related to eosinophil infiltration.
CONCLUSION: The murine model of adoptive transferred myocarditis is suitable for studying the mechanism of eosinophilic myocarditis. A unique pathogenesis of this disorder may be controlled by the synergism of CD4 dominancy in the donor and JAK-STAT signaling in the recipient, which may cause recruitment of eosinophils into heart lesions. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016056     DOI: 10.1159/000095996

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

Review 1.  Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research.

Authors:  Vikrant Rai; Poonam Sharma; Swati Agrawal; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2016-10-20       Impact factor: 3.396

2.  Fatal eosinophilic myocarditis develops in the absence of IFN-γ and IL-17A.

Authors:  Jobert G Barin; G Christian Baldeviano; Monica V Talor; Lei Wu; SuFey Ong; DeLisa Fairweather; Djahida Bedja; Natalie R Stickel; Jillian A Fontes; Ashley B Cardamone; Dongfeng Zheng; Kathleen L Gabrielson; Noel R Rose; Daniela Ciháková
Journal:  J Immunol       Date:  2013-09-18       Impact factor: 5.422

3.  Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model.

Authors:  David K Meyerholz; Michelle A Griffin; Elaine M Castilow; Steven M Varga
Journal:  Toxicol Pathol       Date:  2009-01-29       Impact factor: 1.902

4.  Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy.

Authors:  Yuk-Wah Tsang; Cheng-Chung Huang; Kai-Lin Yang; Mau-Shin Chi; Hsin-Chien Chiang; Yu-Shan Wang; Gabor Andocs; Andras Szasz; Wen-Tyng Li; Kwan-Hwa Chi
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430

5.  Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy.

Authors:  Nicola L Diny; G Christian Baldeviano; Monica V Talor; Jobert G Barin; SuFey Ong; Djahida Bedja; Allison G Hays; Nisha A Gilotra; Isabelle Coppens; Noel R Rose; Daniela Čiháková
Journal:  J Exp Med       Date:  2017-03-16       Impact factor: 14.307

Review 6.  The Roles of Cardiac Fibroblasts and Endothelial Cells in Myocarditis.

Authors:  Yunling Xuan; Chen Chen; Zheng Wen; Dao Wen Wang
Journal:  Front Cardiovasc Med       Date:  2022-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.